Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator's choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC).

被引：0

作者：

Kaklamani, Virginia G.

Bardia, Aditya

Aftimos, Philippe Georges

Cortes, Javier

Lu, Janice M.

Neven, Patrick

Streich, Guillermo

Montero, Alberto J.

Forget, Frederic

Mouret-Reynier, Marie-Ange

Sohn, Joohyuk

Taylor, Donatienne

Harnden, Kathleen Kiernan

Khong, Hung T.

Kocsis, Judit

Dalenc, Florence

Dillon, Patrick Michael

Tonini, Giulia

Grzegorzewski, Kris

Bidard, Francois-Clement

机构：

[1] Univ Texas Hlth Sci Ctr, Houston, TX USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[3] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[4] Quironsalud Grp, Int Breast Canc Ctr, Barcelona, Spain

[5] Univ Europea Madrid, Madrid, Spain

[6] Univ Southern Calif, Los Angeles, CA USA

[7] Univ Ziekenhuizen UZ, Leuven Canc Inst, Leuven, Belgium

[8] Ctr Med Austral, Buenos Aires, Argentina

[9] Case Western Reserve Univ, Cleveland, OH USA

[10] Seidman Canc Ctr, UH, Cleveland, OH USA

[11] Ctr Hosp Ardenne, Site Libramont, Libramont, Belgium

[12] Ctr Jean Perrin, Clermont Ferrand, France

[13] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

[14] Univ Catholic Louvain, CHU UCL Namur, Site Sainte Elisabeth, Namur, Belgium

[15] Inova Schar Canc Ctr, Fairfax, VA USA

[16] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[17] Bacs Kiskun Megyei Korhaz, Kecskemet, Hungary

[18] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France

[19] Univ Virginia Hlth Syst, Charlottesville, VA USA

[20] Menarini Grp, Florence, Italy

[21] Menarini Grp, Stemline Therapeut, New York, NY USA

[22] Inst Curie, Paris, France

[23] Inst Curie, St Cloud, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1100

引用

页数：1

共 50 条

[31] Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups.
Zhao, Joseph J.
Hong, Nicky Wong Zhun
Yap, Dominic Wei Ting
Ong, Rebecca Jia Min
Sundar, Raghav
Lim, Joline Si Jing
Dawood, Shaheenah S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[32] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial (vol 40, 3246, 2022)
Bidard
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23) : 3962 - 3962
[33] Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2-locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection
Aftimos, Philippe
Neven, Patrick
Pegram, Mark
van Oord, Catharina Willemien Menke-van der Houven
Dees, E. Claire
Schroder, Carolien
Jager, Agnes
Bulat, Iurie
Chap, Linnea
Maglakelidze, Marina
Hamilton, Erika
Cristofanilli, Massimo
Ulahannan, Susanna
Boers, Jorianne
Iqbal, Ramsha
Crijanovschi, Adrian
Wolfgang, Curt D.
Tao, Wenli
Sipes, Christina
Malik, Rajesh
Jain, Sarika
CANCER RESEARCH, 2021, 81 (04)
[34] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Rugo, Hope
Bardia, Aditya
Cortes, Javier
Curigliano, Giuseppe
Hamilton, Erika
Hurvitz, Sara
Loibl, Sibylle
Tolaney, Sara
Kaklamani, Virginia
Tonini, Giulia
Matheny, Shannon
Theall, Kathy Puvana
O'Shaughnessy, Joyce
CANCER RESEARCH, 2024, 84 (09)
[35] Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Bardia, Aditya
Cortes, Javier
Bidard, Francois-Clement
Neven, Patrick
Garcia-Saenz, Jose
Aftimos, Phillipe
O'Shaughnessy, Joyce
Lu, Janice
Tonini, Giulia
Scartoni, Simona
Paoli, Alessandro
Binaschi, Monica
Wasserman, Tomer
Kaklamani, Virginia
CLINICAL CANCER RESEARCH, 2024, 30 (19) : 4299 - 4309
[36] A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients
Chan, Arlene
Day, Daphne
Phuong Dinh
Slancar, Michael
Lombard, Janine
Ganju, Vinod
McCarthy, Nicole
Wilson, Rosalind
Faltaos, Demiana
Mathauda-Sahota, Gurpreet
Murphy, Caitlin
CANCER RESEARCH, 2024, 84 (09)
[37] Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
Lin, N. U.
Borges, V. F.
Patel, M. R.
Okera, M.
Meisel, J.
Wesolowski, R.
Pluard, T.
Miller, K. D.
McCarthy, N. J.
Conlin, A. K.
Mahtani, R.
Sabanathan, D.
McCann, K. E.
Roesch, E.
Mathauda-Sahota, G.
Schroeder, J.
Hamilton, E. P.
ANNALS OF ONCOLOGY, 2023, 34 : S338 - S338
[38] EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator's choice (IC) of endocrine therapy (ET) for ER+/HER2-advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.
Bardia, Aditya
Aftimos, Philippe Georges
Jiang, Hai
Bihani, Teeru
Anderson-Villaluz, Alfred T.
Conlan, Maureen G.
Kaklamani, Virginia G.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[39] Updated Data From AMEERA-1: Phase 1/2 Study of Amcenestrant (SAR439859), an Oral Selective Estrogen Receptor Degrader, Combined With Palbociclib in Postmenopausal Women With ER+/ HER2-Advanced Breast Cancer AbstractsY
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (01) : 4 - 14
[40] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Rugo, Hope S.
Bardia, Aditya
Cortes, Javier
Curigliano, Giuseppe
Hamilton, Erika
Hurvitz, Sara A.
Loibl, Sibylle
Kummel, Sherko
Scartoni, Simona
Matheny, Shannon
Theall, Kathy Puyana
O'shaughnessy, Joyce
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32

← 1 2 3 4 5 →